PET-CT for Colorectal Cancer — What It Is Actually Used For

Usually no. NCCN and ESMO guidelines recommend CT of the chest, abdomen and pelvis for staging colorectal cancer at diagnosis — not PET-CT. PET is ordered when a specific finding on CT raises a question that CT alone cannot answer. If PET-CT has been recommended at the start, ask your oncologist which finding prompted it and what the result would change about your treatment plan.

PET-CT can add useful information when a liver lesion is ambiguous on CT — a lesion that takes up FDG is more likely to be active cancer. But PET is not definitive, and small lesions can be missed entirely. Your team may also consider MRI of the liver, which gives more structural detail for certain lesion types. The two scans answer different questions, and your oncologist will decide which is more likely to resolve the uncertainty in your case.

Yes, and this is one of the situations where PET-CT is most useful for colorectal cancer. A rising CEA after treatment suggests recurrence, but early deposits can be too small or in locations CT does not show well. PET-CT has better sensitivity for active disease in this setting. It will not always find the source — mucinous, low-grade or peritoneal recurrence can still be PET-negative — but it is a reasonable next step when CT is inconclusive and CEA continues to rise.

Mucinous colorectal cancer is a recognised limitation of PET-CT. These tumours produce mucin rather than taking up glucose rapidly, so they often have low metabolic activity and do not appear reliably on PET. A negative or faint result in a mucinous cancer does not mean no cancer is present — it may mean PET is the wrong tool. Ask your oncologist whether PET-CT is likely to give interpretable results for your tumour type, or whether CT or MRI would be more informative.

CT shows anatomy — the size and shape of structures in the body. PET adds a layer of metabolic information: it uses a radioactive glucose to show which cells are taking up energy rapidly, as actively dividing cancer cells tend to do. The two are usually done together as a combined PET-CT scan. CT is better for local structural detail; PET is better for detecting active disease spread across the body. They answer different questions, and your team decides which matters most for your specific situation.

Before removing liver metastases, your surgical team needs to know whether the liver is the only site of active disease. If cancer is also present elsewhere — in the lungs, lymph nodes or other organs — operating on the liver alone is unlikely to help, and the plan would need to change. PET-CT before liver surgery checks for exactly this. ESMO guidance supports its use as part of the pre-operative workup for selected patients with colorectal liver metastases.